FDA Approves New Oral Therapy to Treat ALK-positive Lung Cancer

FDA Approves New Oral Therapy to Treat ALK-positive Lung Cancer

PracticeUpdate Editorial Team

  The U.S. Food and Drug Administration today approved Alecensa (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lung cancer (NSCLC) whose disease has worsened after, or who could not tolerate treatment with, another therapy called Xalkori (crizotinib). So we are targeting gene mutations seen in more than one cancer and Lung is the BIG ONE  Anybody else feel; like brave new World Starting to happen.

New Topic Alerts

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s